New dose schedule for J&J bispecific; Layoffs at Ring Therapeutics; Regeneron’s priority review
2024-02-21
优先审批上市批准临床3期加速审批
Plus, news about Enveric Biosciences and Kazia Therapeutics:
Johnson & Johnson’s bispecific gets a new dosing schedule:
The FDA approved a reduced dosing regimen for J&J’s multiple myeloma bispecific antibody Tecvayli, the pharma company
announced
Tuesday evening. The reduced dosing approval comes as the drug’s side effects, such as cytokine release syndrome and serious infections,
are substantial
. The treatment is approved for multiple myeloma patients who have received four prior lines of therapy, but now those who have been in remission for at least six months can move down from a weekly to a biweekly dosing schedule. —
Lei Lei Wu
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。